| Typicality: | 0.595 |
| Saliency: | 0.807 |
| in the second half of 2015 | 4 | temporal |
| xenon → anticipate initiating → phase 2 clinical trial | 5 |
| xenon → expect to initiate → phase 2 clinical trial | 3 |
| xenon → plan to initiate → proof-of-concept phase 2 clinical trial | 3 |
| negative | neutral | positive |
| 0.006 | 0.680 | 0.315 |
| Raw frequency | 11 |
| Normalized frequency | 0.807 |
| Modifier score | 0.500 |
| Perplexity | 91.573 |